The Department of Health – Abu Dhabi (DoH), the Abu Dhabi Investment Office (ADIO), Etihad Airways, and AD Ports Group, have entered into a partnership to strengthen Abu Dhabi’s capabilities as a global pharmaceutical and life sciences distribution hub, leveraging its strategic location, lucrative investment opportunities, and advanced logistics capabilities.
The strategic partnership is a pivotal step in Abu Dhabi’s ongoing efforts to become a leading healthcare destination in the global healthcare landscape. This is in line with the Abu Dhabi Economic Vision 2030.
The collaboration aims to create attractive value propositions for pharmaceutical, biotechnology, and medical technology companies to establish their operations in Abu Dhabi by capitalizing on DoH’s world-class regulatory framework, ADIO’s attractive investment platform, Etihad Cargo’s expertise in air freight, and AD Port Group’s robust logistics infrastructure.
Badr Al Olama Director General ADIO
“Abu Dhabi has made supporting the healthcare and life sciences industry a strategic priority, benefiting our nation and the world. Today, Abu Dhabi stands as a leading hub in this field, with advanced infrastructure and supportive regulations enabling a vibrant community of health-tech companies. This partnership will drive further collaboration to expand the Abu Dhabi ecosystem and unlock new opportunities for the sector’s leading innovators and companies.”
Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Centre at DoH, said that, “Leveraging Abu Dhabi’s strategic location at the gateway to the MENA region, we are pleased to partner with world-class leaders in investment and logistics, offering advanced infrastructure with easy access to regional and global markets. This MoU reaffirms DoH’s commitment to leading the transformation of the regional healthcare ecosystem.”
As part of the agreement, the entities will work together to ensure timely access to innovative healthcare products for patients across the region, enhancing Abu Dhabi’s role in global pharmaceutical supply chains.
Aligned with the emirate’s economic aspirations, the collaboration is expected to attract significant investment in healthcare and logistics, promoting sustainable economic growth and diversification within the healthcare and life sciences sectors.
Further, the partnership also includes plans to support local manufacturing and packaging of pharmaceutical and biotechnology products, in addition to local capability enhancement.
